CTOs on the Move

OmniSYS

www.omnisys.com

 
OmniSYS is a technology company with 25+ years of experience working with pharmacies, payers, providers and pharmaceutical manufacturers. We leverage this unique market insight along with our pharmacy workflow expertise to deliver valuable solutions that help pharmacies thrive in the changing pharmacy landscape. Our solutions help pharmacies engage patients, grow clinical services and improve financial performance. OmniSYS currently serves over 25,000 pharmacies, connects to hundreds of payers and touches millions of patient lives.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.omnisys.com
  • 15950 Dallas Parkway Suite 350
    Dallas, TX USA 75248
  • Phone: 214.459.2574

Executives

Name Title Contact Details

Similar Companies

Arnot Ogden Medical Center

Arnot Ogden Medical Center is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Elmira, NY. To find more information about Arnot Ogden Medical Center, please visit www.aomc.org

Active Ice Inc

Active Ice Inc is a Norman, OK-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Midwestern Connecticut Council on Alcoholism (MCCA)

Midwestern Connecticut Council on Alcoholism (MCCA) is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Midwestern Connecticut Council on Alcoholism (MCCA) is based in Danbury, CT. You can find more information on Midwestern Connecticut Council on Alcoholism (MCCA) at www.mccaonline.com

NDRI National Disease Research Interchange

NDRI National Disease Research Interchange is a Philadelphia, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Scynexis

SCYNEXIS, Inc. is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. Our scientists have extensive experience in the life sciences industry having, together and individually, been involved in the discovery and development of innovative medicines over a broad range of therapy areas. We are developing our lead product candidate, SCY-078, a novel antifungal in Phase 2, as a novel oral and intravenous drug for the treatment of serious and life-threatening invasive fungal infections in humans.